Literature DB >> 11207808

In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig.

N Vibert1, P P Vidal.   

Abstract

For 40 years, the amino acid acetyl-DL-leucine (or isoleucine/Tanganil) has been used in clinical practice to reduce the imbalance and autonomic signs associated with acute vertigo crises. In animal models, acetyl-DL-leucine was shown to accelerate vestibular compensation following unilateral labyrinthectomy, while having only minor effects on normal vestibular function. However, the underlying mechanisms are unknown. In this study, the effect of acetyl-DL-leucine on the activity of central vestibular neurons of the medial vestibular nucleus (MVN) and/or the overall activity of vestibular-related networks was electrophysiologically measured in brainstem slices and in the isolated, in vitro whole brain (IWB) of guinea-pig. Only moderate effects were obtained in normal animals, where both excitatory and inhibitory actions of acetyl-DL-leucine were obtained. However, intracellular recordings from MVN neurons revealed that the nature of the response depended on the resting membrane potential. The neurons excited by acetyl-DL-leucine were significantly hyperpolarized compared to nonsensitive cells, whereas the neurons inhibited by this compound tended to display higher than normal membrane potentials. In accordance with these data, acetyl-DL-leucine reduced the prominent asymmetry characterizing the vestibular-related networks of IWBs taken from previously labyrinthectomized animals, by decreasing the activity of the abnormally depolarized neurons on the hyperactive side. Altogether, our results suggest that acetyl-DL-leucine might act mainly on abnormally hyperpolarized and/or depolarized MVN neurons, by bringing back their membrane potential towards a mean value of -65 to -60 mV. Since in animal models, acute vestibular disorders are associated with asymmetrical spontaneous activities of MVN neurons, this study suggests how acetyl-DL-leucine may reduce acute, vestibular-related imbalances in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207808     DOI: 10.1046/j.0953-816x.2000.01447.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  17 in total

1.  Failure to confirm benefit of acetyl-DL-leucine in degenerative cerebellar ataxia: a case series.

Authors:  Johann Otto Pelz; Christopher Fricke; Dorothee Saur; Joseph Classen
Journal:  J Neurol       Date:  2015-04-11       Impact factor: 4.849

2.  An anecdotal report by an Oxford basic neuroscientist: effects of acetyl-DL-leucine on cognitive function and mobility in the elderly.

Authors:  Frances Platt; Michael Strupp
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

Review 3.  The physiological basis of therapies for cerebellar ataxias.

Authors:  Hiroshi Mitoma; Mario Manto
Journal:  Ther Adv Neurol Disord       Date:  2016-05-20       Impact factor: 6.570

4.  Autoradiography in brain of Macaca fascicularis monkeys after injection of acetyl-DL-leucine [2-14C] (Tanganil).

Authors:  P Benard; H Cousse; T Bengone; C Germain
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

5.  Acetyl-DL-leucine in cerebellar ataxia ([18F]-FDG-PET study): how does a cerebellar disorder influence cortical sensorimotor networks?

Authors:  Sandra Becker-Bense; Lena Kaiser; Regina Becker; Katharina Feil; Carolin Muth; Nathalie L Albert; Marcus Unterrainer; Peter Bartenstein; Michael Strupp; Marianne Dieterich
Journal:  J Neurol       Date:  2022-07-25       Impact factor: 6.682

6.  Vestibular function in patients with Niemann-Pick type C disease.

Authors:  Tatiana Bremova; Siegbert Krafczyk; Stanislavs Bardins; Jörg Reinke; Michael Strupp
Journal:  J Neurol       Date:  2016-08-20       Impact factor: 4.849

7.  Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series.

Authors:  Michael Strupp; Julian Teufel; Maximilian Habs; Regina Feuerecker; Carolin Muth; Bart P van de Warrenburg; Thomas Klopstock; Katharina Feil
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

8.  N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus.

Authors:  Lisa Günther; Roswitha Beck; Guoming Xiong; Heidrun Potschka; Klaus Jahn; Peter Bartenstein; Thomas Brandt; Mayank Dutia; Marianne Dieterich; Michael Strupp; Christian la Fougère; Andreas Zwergal
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 9.  Update on the pharmacotherapy of cerebellar and central vestibular disorders.

Authors:  Roger Kalla; Julian Teufel; Katharina Feil; Caroline Muth; Michael Strupp
Journal:  J Neurol       Date:  2016-04-15       Impact factor: 4.849

10.  Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series.

Authors:  Roman Schniepp; Michael Strupp; Max Wuehr; Klaus Jahn; Marianne Dieterich; Thomas Brandt; Katharina Feil
Journal:  Cerebellum Ataxias       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.